QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
NASDAQ:ADTX

Aditxt (ADTX) Stock Price, News & Analysis

$3.40
+0.36 (+11.84%)
(As of 04:00 PM ET)
Today's Range
$3.05
$3.49
50-Day Range
$3.04
$4.45
52-Week Range
$2.95
$76.40
Volume
287,535 shs
Average Volume
137,124 shs
Market Capitalization
$816,000.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$61.00

Aditxt MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,694.1% Upside
$61.00 Price Target
Short Interest
Healthy
1.79% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.18mentions of Aditxt in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($80.82) to ($51.28) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.35 out of 5 stars

ADTX stock logo

About Aditxt Stock (NASDAQ:ADTX)

Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. It is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.

ADTX Stock Price History

ADTX Stock News Headlines

Aditxt, Inc. (NASDAQ:ADTX) Sees Large Growth in Short Interest
Investors Alert: The Next Big Thing in Weight Loss
History shows biotech breakthroughs like this can turn small investments into staggering fortunes for those with the foresight to get in early. I've isolated the small company behind it all...
Aditxt CEO Provides Short-Term Loan to Bolster Stability
Investors Alert: The Next Big Thing in Weight Loss
History shows biotech breakthroughs like this can turn small investments into staggering fortunes for those with the foresight to get in early. I've isolated the small company behind it all...
Aditxt Stock (NASDAQ:ADTX), Short Interest Report
What's Going On With Aditxt Stock?
Crude Oil Down 4%; Aditxt Shares Spike Higher
Aditxt, Inc. Common Stock (ADTX)
See More Headlines
Receive ADTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aditxt and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/11/2021
Today
3/28/2024
Next Earnings (Estimated)
4/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ADTX
Fax
N/A
Employees
61
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$61.00
High Stock Price Target
$61.00
Low Stock Price Target
$61.00
Potential Upside/Downside
+1,906.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-27,650,000.00
Net Margins
-3,946.13%
Pretax Margin
-3,946.13%

Debt

Sales & Book Value

Annual Sales
$930,000.00
Book Value
$50.04 per share

Miscellaneous

Free Float
236,000
Market Cap
$729,600.00
Optionable
No Data
Beta
1.28
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives


ADTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Aditxt stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aditxt in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ADTX shares.
View ADTX analyst ratings
or view top-rated stocks.

What is Aditxt's stock price target for 2024?

1 brokerages have issued 12-month target prices for Aditxt's stock. Their ADTX share price targets range from $61.00 to $61.00. On average, they expect the company's stock price to reach $61.00 in the next twelve months. This suggests a possible upside of 1,694.1% from the stock's current price.
View analysts price targets for ADTX
or view top-rated stocks among Wall Street analysts.

How have ADTX shares performed in 2024?

Aditxt's stock was trading at $6.63 on January 1st, 2024. Since then, ADTX shares have decreased by 48.7% and is now trading at $3.40.
View the best growth stocks for 2024 here
.

Are investors shorting Aditxt?

Aditxt saw a increase in short interest in March. As of March 15th, there was short interest totaling 35,100 shares, an increase of 102.9% from the February 29th total of 17,300 shares. Based on an average daily volume of 570,800 shares, the days-to-cover ratio is currently 0.1 days. Currently, 1.8% of the company's stock are sold short.
View Aditxt's Short Interest
.

When is Aditxt's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 2nd 2024.
View our ADTX earnings forecast
.

How were Aditxt's earnings last quarter?

Aditxt, Inc. (NASDAQ:ADTX) released its quarterly earnings data on Wednesday, August, 11th. The company reported ($840.00) EPS for the quarter, missing the consensus estimate of ($100.00) by $740.00. Aditxt had a negative net margin of 3,946.13% and a negative trailing twelve-month return on equity of 777.58%.

When did Aditxt's stock split?

Shares of Aditxt reverse split on Friday, August 18th 2023. The 1-40 reverse split was announced on Friday, August 18th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Aditxt own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aditxt investors own include Tesla (TSLA), Dynavax Technologies (DVAX), Boeing (BA), CrowdStrike (CRWD), Genius Brands International (GNUS), Nikola (NKLA), Block (SQ), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV) and Arbutus Biopharma (ABUS).

Who are Aditxt's major shareholders?

Aditxt's stock is owned by a variety of institutional and retail investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Amro A Albanna, Corinne Pankovcin, Paribas Securities Corp Bnp, Shahrokh Shabahang and Thomas J Farley.
View institutional ownership trends
.

How do I buy shares of Aditxt?

Shares of ADTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ADTX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners